CD274 and lung carcinoma: While the most impressive responses to PD-1/PD-L1 blockade have been observed in metastatic melanoma, lung cancer, renal cell carcinoma, and hematologic malignancies [22], it has also recently been shown that triple-negative breast cancer and bladder cancer are responsive to immune checkpoint blockade [32].